Dydo Pharma
Osaka, Japan· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
Japanese pharmaceutical company specializing in rare neurological disease treatments, with recent approval of Firdapse® for Lambert-Eaton myasthenic syndrome in Japan.
Neurology
Technology Platform
Small molecule development focused on potassium channel blockers, particularly amifampridine phosphate (3,4-diaminopyridine) for neuromuscular junction disorders.
Opportunities
Potential expansion of Firdapse® into additional neurological indications and geographic markets, plus opportunity to leverage rare disease expertise for pipeline expansion.
Risk Factors
Single-product dependency risk, potential competition from other amifampridine formulations, and challenges in rare disease market penetration and reimbursement.
Competitive Landscape
Competes with other amifampridine products globally (like Ruzurgi®) but holds first approved product advantage in Japan for LEMS treatment; differentiation through focused rare disease expertise and efficient Japanese regulatory execution.